Development and validation of a next generation sequencing based protocol for 24 chromosome aneuploidy screening of embryos
Study reporting extensive preclinical validation and accuracy assessment of next-generation sequencing (NGS)-based comprehensive aneuploidy screening on single cells. NGS has demonstrated a robust methodology, ready for clinical application in reproductive medicine.
Francesco Fiorentino, Ph.D., Anil Biricik, M.Sc., Sara Bono, B.Sc., Letizia Spizzichino, B.Sc., Ettore Cotroneo, B.Sc., Giuliano Cottone, B.Sc., Felix Kokocinski, Ph.D., Claude-Edouard Michel, Ph.D.
Volume 101, Issue 5, Pages 1375–1382.e2
To validate a next-generation sequencing (NGS)–based method for 24-chromosome aneuploidy screening and to investigate its applicability to preimplantation genetic screening (PGS).
Retrospective blinded study.
Karyotypically defined chromosomally abnormal single cells and whole-genome amplification (WGA) products, previously analyzed by array comparative genomic hybridization (array-CGH), selected from 68 clinical PGS cycles with embryos biopsied at cleavage stage.
Main Outcome Measure(s):
Consistency of NGS-based diagnosis of aneuploidy compared with either conventional karyotyping of single cells or array-CGH diagnoses of single blastomeres.
Eighteen single cells and 190 WGA products from single blastomeres, were blindly evaluated with the NGS-based protocol. In total, 4,992 chromosomes were assessed, 402 of which carried a copy number imbalance. NGS specificity for aneuploidy call (consistency of chromosome copy number assignment) was 99.98% (95% confidence interval [CI] 99.88%–100%) with a sensitivity of 100% (95% CI 99.08%–100%). NGS specificity for aneuploid embryo call (24-chromosome diagnosis consistency) was 100% (95% CI 94.59%–100%) with a sensitivity of 100% (95% CI 97.39%–100%).
This is the first study reporting extensive preclinical validation and accuracy assessment of NGS-based comprehensive aneuploidy screening on single cells. Given the high level of consistency with an established methodology, such as array-CGH, NGS has demonstrated a robust high-throughput methodology ready for clinical application in reproductive medicine, with potential advantages of reduced costs and enhanced precision.
Read the full text at: http://www.fertstert.org/article/S0015-0282(14)00099-5/fulltext